Can estrogen boost the 'Love Hormone' in a rare condition?

NCT ID NCT06460948

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study tested whether a single dose of oral estrogen-progestin can raise oxytocin levels in people with arginine vasopressin deficiency (AVD), a rare condition that also causes low oxytocin. Researchers compared 28 adults—some with AVD and some healthy—to see if oxytocin responses differ and if lower oxytocin relates to anxiety, depression, or quality of life. The goal is to better understand the link between hormones and emotional health in AVD.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Estrogen-progestin (norethindrone acetate-ethinyl estradiol)
What this could lead to
If successful, this could help understand oxytocin deficiency in AVD and point toward future treatments for related anxiety, depression, or social difficulties.
What could go wrong
This is a very early, small pilot study with only 28 participants. Results may not apply to broader populations, and the single-dose design limits conclusions about long-term effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ARGININE VASOPRESSIN DEFICIENCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Diabetes Insipidus, Neurogenic neurohypophyseal diabetes insipidus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.